Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study

Wolfgang Weger; B Gruber; G Ratzinger; PG Sator

Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study

Wolfgang Weger
, B Gruber
, G Ratzinger
, PG Sator

Universitätsklinik für Dermatologie und Venerologie

Publikation: Beitrag in Fachzeitschrift › Konferenzabstract

Originalsprache	Englisch
Seiten (von - bis)	S352-S352
Seitenumfang	1
Fachzeitschrift	Journal of Investigative Dermatology
Jahrgang	143
Ausgabenummer	11
Publikationsstatus	Veröffentlicht - Nov. 2023
Veranstaltung	5th Inflammatory Skin Disease Summit - Vienna, Österreich Dauer: 15 Nov. 2023 → 18 Nov. 2023

Wissenschaftszweige

302 Klinische Medizin

Andere Dateien und Links

Web of Science

Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study
Weger, W. (Autor*in), Gruber, B. (Autor*in), Ratzinger, G. (Autor*in) & Sator, P. (Autor*in)
2023
Aktivität: Vortrag oder Poster › Poster

Dieses zitieren

@article{e48daa9d481944c6a8701da701d3274d,

title = "Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study",

author = "Wolfgang Weger and B Gruber and G Ratzinger and PG Sator",

year = "2023",

month = nov,

language = "English",

volume = "143",

pages = "S352--S352",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Elsevier B.V.",

number = "11",

note = "5th Inflammatory Skin Disease Summit, ISDS 5 ; Conference date: 15-11-2023 Through 18-11-2023",

}

TY - JOUR

T1 - Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study

AU - Weger, Wolfgang

AU - Gruber, B

AU - Ratzinger, G

AU - Sator, PG

PY - 2023/11

Y1 - 2023/11

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001106031700111

M3 - Conference abstract

SN - 0022-202X

VL - 143

SP - S352-S352

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 11

T2 - 5th Inflammatory Skin Disease Summit

Y2 - 15 November 2023 through 18 November 2023

ER -

Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study

Wissenschaftszweige

Andere Dateien und Links

Aktivitäten

Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study

Dieses zitieren